Physiologic Action of Glucagon on Liver Glucose Metabolism
Overview
Affiliations
Glucagon is a primary regulator of hepatic glucose production (HGP) in vivo during fasting, exercise and hypoglycaemia. Glucagon also plays a role in limiting hepatic glucose uptake and producing the hyperglycaemic phenotype associated with insulin deficiency and insulin resistance. In response to a physiological rise in glucagon, HGP is rapidly stimulated. This increase in HGP is entirely attributable to an enhancement of glycogenolysis, with little to no acute effect on gluconeogenesis. This dramatic rise in glycogenolysis in response to hyperglucagonemia wanes with time. A component of this waning effect is known to be independent of hyperglycemia, though the molecular basis for this tachyphylaxis is not fully understood. In the overnight fasted state, the presence of basal glucagon secretion is essential in countering the suppressive effects of basal insulin, resulting in the maintenance of appropriate levels of glycogenolysis, fasting HGP and blood glucose. The enhancement of glycogenolysis in response to elevated glucagon is critical in the life-preserving counterregulatory response to hypoglycaemia, as well as a key factor in providing adequate circulating glucose for working muscle during exercise. Finally, glucagon has a key role in promoting the catabolic consequences associated with states of deficient insulin action, which supports the therapeutic potential in developing glucagon receptor antagonists or inhibitors of glucagon secretion.
Hepatic Metabolic Memory Triggered by AM Exposure to Glucagon Alters Afternoon Glucose Metabolism.
Waterman H, Smith M, Farmer B, Yankey K, Howard T, Kraft G bioRxiv. 2025; .
PMID: 40060516 PMC: 11888283. DOI: 10.1101/2025.02.25.639957.
Galsgaard K, Elmelund E, Hunt J, Smits M, Grevengoed T, Christoffersen C Physiol Rep. 2025; 13(4):e70235.
PMID: 39985139 PMC: 11845321. DOI: 10.14814/phy2.70235.
Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.
Hu C, Chen Y, Yin X, Xu R, Yin C, Wang C Signal Transduct Target Ther. 2025; 10(1):39.
PMID: 39948335 PMC: 11825823. DOI: 10.1038/s41392-024-02098-3.
Waterman H, Moore M, Smith M, Farmer B, Yankey K, Scott M Diabetes. 2024; 74(3):270-281.
PMID: 39602425 PMC: 11842597. DOI: 10.2337/db24-0786.
Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson's Disease.
Tanvir A, Jo J, Park S Cells. 2024; 13(22).
PMID: 39594624 PMC: 11592965. DOI: 10.3390/cells13221876.